FDA Accepts Biohaven’s Resubmitted Vyglxia Application
The FDA accepted Biohaven’s resubmitted application seeking approval of Vyglxia for spinocerebellar ataxia.
By Colin KellaherBiohaven shares rose sharply in premarket trading Thursday after the clinical-stage biopharmaceutical company said the U.S. Food and Drug Administration has accepted its resubmitted application seeking approval of Vyglxia for the rare genetic disease spinocerebellar ataxia.Shares o…